Early Access — free while we kick the tires
EdgarHawk

MIRM Mirum Pharmaceuticals, Inc. Insider Trading

Latest: CEO Sold $2.9M of Shares · Jun 2026
1 filing analyzed · Latest 2026-06-02
Insider buys
0
Insider sells
1
Unique insiders
1
Direction
Net selling
June 2026
2026-06-02
medium
Christopher Peetz Sell
CHIEF EXECUTIVE OFFICER
30,000 shares
$2,875,103
@ $95.84
Significance 5/10

CEO Peetz sells 30,000 shares ($2.9M) via scheduled 10b5-1 plan; retains 194,309 shares plus 128,487 stock options

Christopher Peetz executed 6 separate sales totaling 30,000 shares for $2,875,103.34 at prices ranging from $94.64 to $99.66, reducing his non-derivative holdings from 224,309 to 194,309 shares (-13.4%). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-02, making it scheduled rather than discretionary. The sales occurred as the stock trades at $92.17, down 19.8% from its 52-week high of $114.99, though it is up 30 days (-4.5%) and up 90 days (-0.9%). At MIRM specifically, Peetz's prior 5 sales show mixed near-term outcomes: his most recent sale on 2026-03-16 was followed by 30-day and 90-day gains of 4.8% and 4.7% respectively, while his 2026-02-02 sale saw subsequent declines of 9.9% and 6.6%. The company remains unprofitable (net income of $-790,155,000.00 in the most recent period) despite annual revenue growth of +54.7%, reflecting an early-stage or turnaround profile.

Get alerts for MIRM

Add MIRM to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access